Answers are grounded in this paper and cite their sources.
Genetic analysis reveals elevated circulating MCP-1 increases stroke risk in predisposed individuals, suggesting targeting inflammatory chemokine pathways could reduce stroke incidence.
Genetic predisposition to elevated circulating levels of MCP-1 is associated with higher risk of stroke, in particular with large-artery stroke and cardioembolic stroke. Whether targeting MCP-1 or its receptors can lower stroke incidence requires further study.
No takes yet. Share an insight, caveat, or question.
Georgakis et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: